PolyPid Terminated European Licensing Agreement
The company has regained commercialization rights for its D-PLEX100 product in Europe after a mutual exit.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Do you generally trust that long-term business partnerships in the pharmaceutical industry prioritize stable patient care?
PolyPid and ADVANZ PHARMA have mutually terminated their 2022 licensing agreement for the commercialization of D-PLEX100. As a result of this decision, full rights for the product in Europe have reverted back to PolyPid.
Why it matters
The termination allows PolyPid to reassess its commercial strategy for Europe after completing key regulatory milestones. The company is now positioned to evaluate new partnerships for the drug following its previous work on the Phase 3 SHIELD II trial.
The companies ended an exclusive license, distribution, and supply agreement that originated in 2022. PolyPid continues to manage its North American commercialization partnership with Azurity Pharmaceuticals.
The players
PolyPid
PolyPid is a pharmaceutical company headquartered in Petach Tikva, Israel, focused on developing targeted, prolonged-release therapeutics.
ADVANZ PHARMA
ADVANZ PHARMA is a pharmaceutical company that focuses on the commercialization of complex medicines across Europe.
Azurity Pharmaceuticals
Azurity Pharmaceuticals is a company that maintains a North American commercialization partnership with PolyPid.
The details
PolyPid, based in Petach Tikva, Israel, is now seeking new paths for its D-PLEX100 product. The company has already moved forward with a New Drug Application to the FDA and a marketing authorization application submitted to the EMA.
Timeline
The original license agreement was signed in 2022.
PolyPid filed its Annual Report on Form 20-F on February 25, 2026.
The termination of the license agreement was announced on October 1, 2026.
Market Landscape
This move marks a shift in how PolyPid handles the global commercialization of assets that have successfully cleared the Phase 3 SHIELD II trial. The company is now balancing its North American strategy with Azurity Pharmaceuticals against an open European territory.
The agreement termination does not impact immediate patient access or retail pricing for the public. It signals a strategic shift for the company that may eventually influence which medical facilities or regions receive the D-PLEX100 treatment once it clears final regulatory review.
The takeaway
Licensing agreements are often adjusted as a company transitions from the clinical trial phase to the regulatory approval stage. This flexibility allows firms to realign their geographic strategies for maximum long-term commercial impact.
Further reading
For broader trends in medical industry partnerships, visit the Healthcare section.
More information
For more information on the company, visit the Company information and corporate website.
Live Poll
Do you generally trust that long-term business partnerships in the pharmaceutical industry prioritize stable patient care?
